

TRegRx Has Secured a Foundational U.S. Platform Patent for Novel Restoration of Regulatory T-Cell (TReg) Function

Patent strengthens proprietary position around correcting impaired IL-2 receptor signaling and supports development of therapies for autoimmune and inflammatory diseases

Palo Alto, CA — July 28, 2026 — TRegRx, Inc., a biotechnology company developing therapies designed to restore regulatory T-cell function and restore immune tolerance, announced the issuance of U.S. Patent No. 12,673,109, titled *“Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders.”*

Issued by the United States Patent and Trademark Office on July 7, 2026, the patent establishes an important component of TRegRx's intellectual property portfolio and supports the company's development of novel therapeutic approaches targeting regulatory T-cell to correct Treg dysfunction.

TRegRx's platform is based on the discovery of a correctable defect in interleukin-2 receptor signaling in Tregs from patients with autoimmune diseases. The company is developing therapeutic strategies intended to restore this signaling pathway to improve Treg function and re-establish immune tolerance without broadly suppressing the immune system.

Tregs are responsible for controlling inflammatory activity to prevent the immune system from attacking healthy tissue. Impaired Treg function is implicated in numerous autoimmune, inflammatory and allergic diseases.

“This patent provides important protection for a differentiated approach to restoring immune regulation,” said **Clarence R. Hurt, Chief Scientist** of TRegRx. “Rather than treating only the downstream symptoms of autoimmune disease, our objective is to correct an underlying defect in regulatory T-cell function to enable the immune system to restore self tolerance.”

A Platform Approach to Immune Restoration

TRegRx has developed a platform of IL-2 fusion protein drug conjugates that combines targeted delivery of drugs to Tregs to block degradation of IL-2 receptor second messenger proteins that are required for Treg function.

The company's preclinical research has demonstrated proof of concept across multiple models of immune-mediated disease, including:

- Systemic lupus erythematosus
- Multiple sclerosis
- Type 1 diabetes
- Allergic asthma

These findings support the potential for a portfolio of therapeutic candidates addressing diseases in which impaired immune tolerance plays a central role.

"Our research suggests that the IL-2 signaling defect observed in dysfunctional regulatory T cells is pharmacologically correctable," said **Dr. Garry Fathman, Co-Founder and Scientific Advisor**. "This creates the potential to develop targeted therapies that act upstream in the disease processes by restoring the body's natural mechanisms of autoimmune control."

Positioned for Strategic Development

The issuance of U.S. Patent No. 12,673,109 provides TRegRx with a stronger foundation for advancing its lead development program and expanding its pipeline of immune-restorative therapies.

The company is seeking strategic and financial partners to support:

- Lead-candidate selection and optimization
- Pharmacokinetic and pharmacodynamic studies
- IND-enabling toxicology and preclinical development
- Process development and GMP manufacturing
- Expansion into additional autoimmune and inflammatory indications

TRegRx is actively evaluating pharmaceutical collaborations, licensing transactions, co-development relationships and investment opportunities with organizations seeking differentiated approaches to immune tolerance and regulatory T-cell biology.

"The immunology sector is increasingly focused on therapies capable of resetting or reprogramming the immune system," said **Michael Pavia, CEO**. "TRegRx offers potential partners a proprietary platform, compelling preclinical evidence and a development strategy directed at a fundamental mechanism of immune dysregulation."

About TRegRx

TRegRx, Inc., formerly IL-2Rx, Inc., is a biotechnology company developing novel therapies intended to restore regulatory T-cell function and re-establish immune tolerance.

The company's scientific platform addresses a correctable defect in interleukin-2 receptor signaling in regulatory T cells. TRegRx has applied this discovery to the development of targeted therapeutic candidates for autoimmune, inflammatory and allergic diseases.

TRegRx's programs are supported by an expanding intellectual property portfolio and preclinical proof-of-concept research in multiple disease models.

Partnership and Investment Inquiries

Dr. Clarence R. Hurt

TRegRx, Inc.

crhurt@tregrx.com

<https://tregrx.com>

Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning the potential characteristics and benefits of TRegRx's technology, the development of product candidates, preclinical and clinical development activities, potential therapeutic indications, intellectual property protection, financing activities and prospective strategic collaborations.

Forward-looking statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied. TRegRx undertakes no obligation to update any forward-looking statement except as required by applicable law.